pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
TESARO Bio Netherlands
TESARO Bio Netherlands B.V.
TESARO Bio Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Ovarian Neoplasms, Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer, Recurrent or primary advanced (Stage II
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 23
- Patents
- 0
PR-30-5017-C
Phase 3 · small molecule · Homologous recombination deficiency advanced ovarian cancer
PR-30-5017-C for Homologous recombination deficiency advanced ovarian cancer is a Phase 3 program (small_molecule) at TESARO Bio Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code PR-30-5017-C
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TESARO Bio Netherlands B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Homologous recombination deficiency advanced ovarian cancer
- Status
- active
- Trials
- 1